Tags

Type your tag names separated by a space and hit enter

Petasins in the treatment of allergic diseases: results of preclinical and clinical studies.
Int Arch Allergy Immunol 2002; 129(2):108-12IA

Abstract

Plant extracts are causing an increased interest in the treatment of many chronic diseases, including asthma and other allergic diseases. Several laboratories characterized petasins (petasin, isopetasin, and neopetasin) isolated from extracts of butterbur (Petasites hybridus) as pharmacologically active components, which inhibit leukotriene synthesis in leukocytes. The molecular mechanisms by which petasins abrogate inflammatory effector cell functions have, at least partially, been identified. In vitro studies revealed that petasins may have several intracellular targets and this may depend on the stereoisomer used. In an open clinical trial in patients suffering from allergic rhinitis, a reduction of leukotriene and histamine levels in nasal fluids was associated with the butterbur extract administration. To better evaluate the clinical value in this particular allergic disease, the clinical efficacy of the drug was compared with an established antihistamine treatment scheme in a double-blind study; no significant difference was observed between the two treatment groups. In this article, we critically review recently published work and summarize the current stage in the pharmacological characterization of butterbur extracts.

Authors+Show Affiliations

Department of Pharmacology, University of Bern, Switzerland.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

12403927

Citation

Thomet, O A R., and H-U Simon. "Petasins in the Treatment of Allergic Diseases: Results of Preclinical and Clinical Studies." International Archives of Allergy and Immunology, vol. 129, no. 2, 2002, pp. 108-12.
Thomet OA, Simon HU. Petasins in the treatment of allergic diseases: results of preclinical and clinical studies. Int Arch Allergy Immunol. 2002;129(2):108-12.
Thomet, O. A., & Simon, H. U. (2002). Petasins in the treatment of allergic diseases: results of preclinical and clinical studies. International Archives of Allergy and Immunology, 129(2), pp. 108-12.
Thomet OA, Simon HU. Petasins in the Treatment of Allergic Diseases: Results of Preclinical and Clinical Studies. Int Arch Allergy Immunol. 2002;129(2):108-12. PubMed PMID: 12403927.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Petasins in the treatment of allergic diseases: results of preclinical and clinical studies. AU - Thomet,O A R, AU - Simon,H-U, PY - 2002/10/31/pubmed PY - 2002/12/11/medline PY - 2002/10/31/entrez SP - 108 EP - 12 JF - International archives of allergy and immunology JO - Int. Arch. Allergy Immunol. VL - 129 IS - 2 N2 - Plant extracts are causing an increased interest in the treatment of many chronic diseases, including asthma and other allergic diseases. Several laboratories characterized petasins (petasin, isopetasin, and neopetasin) isolated from extracts of butterbur (Petasites hybridus) as pharmacologically active components, which inhibit leukotriene synthesis in leukocytes. The molecular mechanisms by which petasins abrogate inflammatory effector cell functions have, at least partially, been identified. In vitro studies revealed that petasins may have several intracellular targets and this may depend on the stereoisomer used. In an open clinical trial in patients suffering from allergic rhinitis, a reduction of leukotriene and histamine levels in nasal fluids was associated with the butterbur extract administration. To better evaluate the clinical value in this particular allergic disease, the clinical efficacy of the drug was compared with an established antihistamine treatment scheme in a double-blind study; no significant difference was observed between the two treatment groups. In this article, we critically review recently published work and summarize the current stage in the pharmacological characterization of butterbur extracts. SN - 1018-2438 UR - https://www.unboundmedicine.com/medline/citation/12403927/full_citation L2 - https://www.karger.com?DOI=10.1159/000065884 DB - PRIME DP - Unbound Medicine ER -